CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
CDZ173 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02775916
NCT02775916Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome

Novartis Pharmaceuticals·interventional·Posted May 18, 2016·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating CDZ173 and Placebo for Primary Sjögren's Syndrome. Completed, enrolled 30 participants across 2 sites in 2 countries.

Detailed Summary

This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sjögren's Syndrome
CountriesGermany, Hungary
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 18, 2016
Enrollment StartJun 1, 2016
Primary CompletionMay 17, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.1 years ago

Interventions

CDZ173drug

Placebodrug